hMAO-B-IN-4 (compound B10) is a selective, reversible and blood-brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC50 value and a Ki value of 0.067 and 0.03 μM, respectively. hMAO-B-IN-4 inhibits hMAO-A with an IC50 value of 33.82 μM. hMAO-B-IN-4 can be used for Alzheimer's disease (AD) and Parkinson's disease (PD) research[1].
hMAO-B-IN-4 (0-40 μM) 对 hMAO-B 相比于 hMAO-A 具有高选择性,SI 值为 504.791[1]。
hMAO-B-IN-4 (0-40 μM) 抑制 hMAO-A 和 hMAO-B,IC50 值分别为 33.821 和 0.067 μM[1]。
[1]. Sudevan ST, et al. Introduction of benzyloxy pharmacophore into aryl/heteroaryl chalcone motifs as a new class of monoamine oxidase B inhibitors. Sci Rep. 2022 Dec 27;12(1):22404.
















